When to Consider Allogeneic Transplantation in CML

Tyrosine kinase inhibitor (TKI) therapy has radically altered the treatment strategy for chronic myeloid leukemia. Allogeneic transplantation, which over a decade ago was considered the definitive therapy for CML, is now appropriately used in cases where all TKIs are not tolerated, in cases of resistance to TKI therapy, or when the disease progresses from chronic phase to accelerated or blast phase.

Source: Clinical Lymphoma, Myeloma and Leukemia - July 31, 2016 Category: Hematology Authors: Jerald Radich Tags: SOHO Supplement 2016 Source Type: research